Azilect® (Rasagiline) is indicated for the treatment of idiopathic PD as monotherapy or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Azilect® got China Food and Drug Administration (CFDA) formal approval on June 19th, 2017. Azilect® with its safety, convenient once-daily dosing, and potentially neuroprotective effect has been highly recommended by international and local guidelines of PD treatment.